Using advanced CAR T cells to target solid tumors more safely
Hijacking the T cell machinery for logic-gated CAR T cell control
['FUNDING_OTHER'] · DANA-FARBER CANCER INST · NIH-11134804
This study is working on a new way to make CAR T cell therapy safer and more effective for people with solid tumors and other conditions, so patients can have better treatment options without as many side effects.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11134804 on ClinicalTrials.gov |
What this research studies
This research focuses on improving CAR T cell therapy, which has been effective for certain blood cancers but struggles with solid tumors due to shared antigens with normal tissues. The team is developing a new approach that activates CAR T cells only when multiple specific antigens are present, reducing the risk of harmful side effects. By optimizing this technology, they aim to expand the use of CAR T cells to treat solid tumors and other conditions like myeloid malignancies and autoimmune diseases. Patients may benefit from a more effective and safer cancer treatment option.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with solid tumors or myeloid malignancies who have not responded to standard treatments.
Not a fit: Patients with early-stage cancers or those whose tumors do not express the targeted antigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment for patients with solid tumors and other related conditions.
How similar studies have performed: While CAR T cell therapy has shown success in treating blood cancers, this novel approach for solid tumors is largely untested and represents a new frontier in cancer treatment.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAJZNER, ROBBIE G. — DANA-FARBER CANCER INST
- Study coordinator: MAJZNER, ROBBIE G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancers